Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 104 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis (MS) - Relapsing-remitting Clear all

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: sirolimus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 58 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Ocrevus; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 27
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 24 more

Conditions: Multiple Sclerosis
Interventions: ALKS 8700; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 74
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Multiple Sclerosis
Interventions: Glatiramer acetate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: natalizumab, standard of care; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT); Procedure · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 23
States / cities: Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Provigil (modafinil); Drug
Lead sponsor: Institute for Clinical Research; Other
Eligibility: 20 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: DAC-HYP; Biological
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Step Tracking, Water Tracking; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years to 59 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 4
States / cities: Columbus, Ohio • Houston, Texas • Seattle, Washington

Conditions: Multiple Sclerosis
Interventions: [18F]Florbetapir PET imaging; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years to 60 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BAF312; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 56 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more

Conditions: Multiple Sclerosis (MS) Relapsing Remitting
Interventions: Powered Hip Flexion Orthosis (Hypershell X); Device
Lead sponsor: University of Dayton; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Ofatumumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Daclizumab; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Dimethyl Fumarate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: St Louis, Missouri • Seattle, Washington

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BrainHQ cognitive training, BrainHQ control games; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 60 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Multiple Sclerosis
Interventions: Betaseron (Interferon beta-1b, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 3 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 19 Years to 58 Years
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions: Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia; Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor

Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

The Synergistic Effects of AIH and FES in Persons With MS

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Behavior and Activity Monitoring in MS

High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Effect of Computerized Cognitive Training in Persons With MS

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS